Benzinga · Sep 11, 2026
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320
Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.
NASDAQ · CRL
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
$273.41
Up+$9.40 (+3.44%)
Updated Sep 17, 2026, 3:20 PM
SID Score
6.2/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 9.57B
- P/E ratio
- -137.99
- Dividend yield
- 0.00%
- 52-week range
- $146.20 – $303.31
- Volume
- 1.01M
- Avg. volume
- 1.03M
Price performance
CRL price history
1M range · 0 trading sessions · Daily adjusted prices
CRL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest CRL news
The latest Smart Investors Daily articles mentioning CRL.
Stock researchCompany · Overview
CRL research
Overview
Company profile and research snapshot.
Company profile
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $191.50
- Implied upside
- —
- Analysts
- 22
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Evercore ISI Group | Outperform | — |
| Aug 10, 2026 | TD Cowen | Buy | — |
| Aug 7, 2026 | Morgan Stanley | Overweight | — |
| Aug 6, 2026 | JP Morgan | Overweight | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
WILMINGTON, Mass., September 08, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity.
Yahoo · Sep 4, 2026
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fintel · Aug 28, 2026
Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
